Why the study?
Does the addition of CRT to ICD improve psychological functioning and quality of life in heart failure patients?
Observational (n=99)
Yes
Does the addition of CRT to ICD improve psychological functioning and quality of life in heart failure patients?
Absolute Event Rate: 16% vs 7%
p-value: p=0.01
Although CRTD improves mental and disease-specific QoL in heart failure patients, it is associated with worse device acceptance compared to ICD alone at 9 months.
Warrants monitoring for depressive symptoms post-CRTD; leaves open net psychological benefit of CRT addition versus ICD in HF.
BACKGROUND: Cardiac resynchronization therapy (CRT) is a treatment for heart failure (HF) that improves cardiac, functional, and quality of life (QoL) outcomes. This study was designed to examine the effect of the addition of CRT (CRTD) to the implantable cardioverter defibrillator (ICD) on psychological functioning. METHODS AND RESULTS: Overall, 99 participants completed batteries before and 9 months after ICD or CRTD implantation in a registry of HF patients receiving device treatment in 3 US centers. Measures included validated indices of mental health (State Trait Anxiety Inventory, Patient Health Questionnaire: Depression) and generic and disease/device-specific QoL (Medical Outcomes Study-Short Form-12, Kansas City Cardiomyopathy Questionnaire, Florida Patient Acceptance Survey, Florida Shock Anxiety Scale). Mixed between-within analyses of covariance were employed to compare device groups on each outcome controlling for cardiac and demographic covariates. Clinically significant anxiety was elevated in both groups at both time points (57% CRTD at baseline, 29% CRTD 9 months, 44% ICD at baseline, 45% ICD 9 months). Clinically significant depressive symptoms were high at baseline (38% CRTD, 31% ICD), but dropped at follow-up (16% CRTD, 7% ICD; P = 0.01). Participants with CRTD had improved mental component and disease-specific QoL following CRT; however, CRTD patients had worse QoL, worse mental component QoL at baseline, and worse device acceptance at 9-month follow-up than patients with ICDs (all P < 0.05). CONCLUSIONS: Evidence of low QoL, psychological functioning, and device acceptance provides the impetus to increase research on well-being of HF patients being implanted with CRTD in research and clinical work.
No takes yet. Share an insight, caveat, or question.
Ford et al. (2013) conducted an observational in Heart failure (n=99). Cardiac resynchronization therapy with defibrillator (CRTD) vs. Implantable cardioverter defibrillator (ICD) was evaluated on Clinically significant depressive symptoms at 9 months (p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: